Although they displayed good cytotoxic potency on human NSCLC lines containing different expressions of the EGFR wild‐type and mutant forms, the first exhibited the most favorable in vitro pharmacokinetic profile, while the latter revealed anti‐EGFR and anti‐microtubule actions. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.